Jeffrey Gregg received his M.D. in 1994, from UCLA. He then entered a Pathology Residency and Genetics Fellowship at UCLA. At UCLA, he trained with Dr. Nelson and focused his research efforts on developing microarray technology. In 1998, he joined the faculty as an Assistant Professor of Pathology and Director of Molecular Diagnostics at UC Davis.
Currently, Jeffrey Gregg serves as Associate Professor of Pathology, Director of Molecular Diagnostics, Department of Pathology, and Director of the Gene Expression Shared Resources for the UC Davis Cancer Center and MIND Institute. His current research focuses on mouse models of mammary carcinoma including a model for ductal carcinoma in-situ (DCIS). With the DCIS model, Jeffrey Gregg is working on strategies for chemoprevention and nutritional intervention. In addition, his laboratory is currently identifying genes involved or requited for progression to invasive carcinoma and metastasis in these models.
In the area of autism, Jeffrey Gregg is utilizing genomic technologies to identify biomarkers and genetic aberrations in children with autism. With gene expression profiling, he is utilizing blood genomics, transcriptional profiling of whole blood, to identify genes that are differentially expressed between children with autism and other control populations. With DNA, he is utilizing microarray technology to identify DNA aberrations that are associated with autism. This technology offers the ability to identify aberrations in the kb size range in contrast to the Mb size traditional cytogenetics offers.
In the microarray field, Jeffrey Gregg is the Director of the Genomics Shared Resource for the UC Davis Cancer Center and MIND Institute. His laboratory performs hundreds of microarray experiments each year. Currently Jeffrey Gregg offers traditional gene expression profiling but more recently offers SNP arrays, CGH arrays, and ChiP-on-ChiP arrays.